Video

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

In April 2019, we announced a collaboration with AstraZeneca to design and develop new treatments for disease beginning with chronic kidney disease and idiopathic pulmonary fibrosis.

By combining our AI and machine learning capabilities with AstraZeneca’s disease area expertise and large, diverse datasets, we hope to improve our understanding of complex disease biology and more quickly identify new potential drug targets.

Our biologists, chemists, engineers, informaticians and data scientists, are working together with our peers at AstraZeneca  to provide new opportunities in understanding and targeting these diseases. In this video, scientists from the centre of the project chart the progress of the collaboration and share their reflections on changing the way we do drug discovery, to enable more efficient and data-driven development  of new medicines.

In our opinion,  partnerships aren’t forged on paper. You can’t write a partnership into being. It has to be based on a professional respect, shared ambition and a common set of values. For us this is the fusion of human expertise with technological innovation. That collision of capabilities is what will help us work  together to  help more people live longer, healthier lives.


More Posts

You Might Also Like

News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022